89BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.26 USD | +0.12% |
|
-9.03% | -26.05% |
| Apr. 17 | 89bio, Inc. Appoints Martin Babler to Its Board of Directors | CI |
| Apr. 03 | 89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 362.5 | 484.4 | 265.1 | 592.4 | 1,041 | 786.6 | - | - |
| Enterprise Value (EV) 1 | 362.5 | 484.4 | 265.1 | 592.4 | 487 | 385.4 | 596.5 | 562.8 |
| P/E ratio | -1.07 x | -7.91 x | -2.92 x | -4.34 x | -5.59 x | -3.73 x | -3.04 x | -3.18 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | 839 x | 360 x | 30.5 x |
| EV / Revenue | - | - | - | - | - | 411 x | 273 x | 21.8 x |
| EV / EBITDA | -13.6 x | -9.83 x | -2.96 x | -5.8 x | -3.22 x | -1.73 x | -2.19 x | -1.84 x |
| EV / FCF | -14.2 x | -10.4 x | -3.45 x | -7.31 x | -3.77 x | -1.97 x | -2.4 x | -2.1 x |
| FCF Yield | -7.06% | -9.57% | -29% | -13.7% | -26.5% | -50.7% | -41.6% | -47.5% |
| Price to Book | - | - | - | - | 1.48 x | 2.05 x | 4.83 x | 5.02 x |
| Nbr of stocks (in thousands) | 13,789 | 19,879 | 20,282 | 46,537 | 93,206 | 95,225 | - | - |
| Reference price 2 | 26.29 | 24.37 | 13.07 | 12.73 | 11.17 | 8.260 | 8.260 | 8.260 |
| Announcement Date | 3/18/20 | 3/24/21 | 3/24/22 | 3/10/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | 0.9375 | 2.188 | 25.77 |
| EBITDA 1 | -26.62 | -49.3 | -89.66 | -102.2 | -151.2 | -222.3 | -272.4 | -305.4 |
| EBIT 1 | -26.64 | -49.36 | -89.74 | -102.2 | -151.2 | -208 | -254.8 | -270 |
| Operating Margin | - | - | - | - | - | -22,183.18% | -11,649.17% | -1,047.74% |
| Earnings before Tax (EBT) 1 | -57.2 | -49.56 | -90.27 | -102 | -138.3 | -191.4 | -247.6 | -272.5 |
| Net income 1 | -57.42 | -49.5 | -90.12 | -102 | -142.2 | -194 | -254.3 | -274.3 |
| Net margin | - | - | - | - | - | -20,690.68% | -11,623.12% | -1,064.58% |
| EPS 2 | -24.49 | -3.080 | -4.480 | -2.930 | -2.000 | -2.213 | -2.716 | -2.597 |
| Free Cash Flow 1 | -25.6 | -46.37 | -76.84 | -81.1 | -129.2 | -195.3 | -248.2 | -267.5 |
| FCF margin | - | - | - | - | - | -20,827.2% | -11,348.01% | -1,038.23% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/18/20 | 3/24/21 | 3/24/22 | 3/10/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | 0.625 | 0.625 | - |
| EBITDA | - | - | - | -24.72 | - | - | - | - | -39.34 | - | - | - | - | - | - |
| EBIT 1 | -28.21 | -26.24 | -25.11 | -24.74 | -27.04 | -25.36 | -28.52 | -42.13 | -39.34 | -41.21 | -45.74 | -50.5 | -54.87 | -60.24 | -59.83 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | -8,778.84% | -9,638.05% | - |
| Earnings before Tax (EBT) 1 | -28.33 | -26.44 | -25.56 | -25.05 | -26.8 | -24.59 | -28.84 | -38.39 | -34.72 | -36.37 | -41.48 | -45.95 | -51.43 | -57.48 | -55.88 |
| Net income 1 | -28.33 | -63.83 | -25.56 | -25.05 | -26.8 | -24.6 | -28.84 | -38.39 | -34.72 | -40.24 | -41.82 | -46.86 | -51.88 | -57.36 | -55.88 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | -8,300.04% | -9,177.3% | - |
| EPS 2 | -1.410 | -1.300 | -1.260 | -1.230 | -0.5700 | -0.4800 | -0.5400 | -0.5200 | -0.4500 | -0.5000 | -0.4695 | -0.5246 | -0.5775 | -0.6339 | -0.5935 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/11/21 | 3/24/22 | 5/11/22 | 8/11/22 | 11/10/22 | 3/10/23 | 5/8/23 | 8/9/23 | 11/9/23 | 2/29/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | - | - | - | - | 554 | 401 | 190 | 224 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -25.6 | -46.4 | -76.8 | -81.1 | -129 | -195 | -248 | -268 |
| ROE (net income / shareholders' equity) | -155% | -33.8% | -54.8% | -73.5% | -41.3% | -46.2% | -90.1% | -173% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | - | 7.540 | 4.020 | 1.710 | 1.640 |
| Cash Flow per Share 2 | -10.90 | -2.870 | -3.820 | -0.7800 | -1.820 | -2.450 | -3.140 | - |
| Capex 1 | 0.14 | 0.13 | 0.06 | 0.01 | 0 | 1.53 | 2.03 | 3.06 |
| Capex / Sales | - | - | - | - | - | 163.71% | 92.89% | 11.87% |
| Announcement Date | 3/18/20 | 3/24/21 | 3/24/22 | 3/10/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.26
USD
Average target price
31.89
USD
Spread / Average Target
+286.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.05% | 787M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ETNB Stock
- Financials 89bio, Inc.
